Interferon Alpha-2a Treatment for Post-Uveitic Refractory Macular Edema

被引：15
|
作者：
De Simone, L. [1 ]
Sangiovanni, A. [1 ]
Aldigeri, R. [2 ]
Mastrofilippo, V. [1 ,3 ]
Bolletta, E. [1 ]
Invernizzi, A. [4 ,5 ]
Fares, L. [6 ]
Pipitone, N. [7 ]
Fontana, L. [3 ]
Salvarani, C. [7 ,8 ]
Cimino, L. [1 ]
机构：
[1] Azienda USL IRCCS, Ocular Immunol Unit, Reggio Emilia, Italy
[2] Univ Parma, Med & Surg Dept, Parma, Italy
[3] Azienda USL IRCCS, Ophthalmol Dept, Reggio Emilia, Italy
[4] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Eye Clin, Milan, Italy
[5] Univ Sydney, Save Sight Inst, Sydney, NSW, Australia
[6] Azienda USL IRCCS, Pharm Dept, Reggio Emilia, Italy
[7] Azienda USL IRCCS, Div Rheumatol, Reggio Emilia, Italy
[8] Univ Modena & Reggio Emilia, Rheumatol Unit, Modena, Italy
来源：
OCULAR IMMUNOLOGY AND INFLAMMATION | 2020年 / 28卷 / 02期
关键词：
IFN; Interferon alpha-2a; macular edema; post-uveitic; uveitis; LONG-TERM EFFICACY; THERAPY;
D O I：
10.1080/09273948.2019.1589526
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
Purpose: To assess the efficacy of interferon (IFN) alpha-2a in the treatment of post-uveitic refractory macular edema (ME). Methods: Retrospective cohort of patients with post-uveitic refractory ME, who received subcutaneous IFN alpha-2a injections for at least 3 months. Baseline central macular thickness (CMT) and best-corrected visual acuity (BCVA) were compared with those at follow-up visits up to 12 months. Results: Thirty-seven patients were included. Treatment duration (median [interquartile range]) was 14[8-24] months with a follow-up of 17[10-38] months. CMT (mean [standard deviation]) decreased from 438[140] to 335[119] mu m after 1 month (p < 0.0001) and remained significantly lower up to 12 months (286[98] mu m, p = 0.001). BCVA (0.48[0.33] logMAR at baseline) improved by 0.26[0.33] logMAR (p = 0.001) at 12 months. There were 14 recurrences. Seven patients had treatment side effects, without serious adverse events. Conclusions: IFN alpha-2a was effective, safe, and well tolerated in treating post-uveitic refractory ME.
引用
收藏
页码：322 / 328
页数：7
相关论文
共 50 条
  • [21] Treatment Outcomes of Intravitreal Aflibercept for Uveitic Macular Edema
    Oyeniran, Enny
    Bhandari, Sanjeeb
    Amir, Ali
    Soifer, Matias
    Bellur, Sunil
    Vitale, Susan
    Sen, H. Nida
    Kodati, Shilpa
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2024,
  • [22] Treatment of Non-infectious Uveitic Macular Edema with the Intravitreal Dexamethasone Implant
    Nobre-Cardoso, Joao
    Champion, Emmanuelle
    Darugar, Adil
    Fel, Audrey
    Lehoang, Phuc
    Bodaghi, Bahram
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2017, 25 (04) : 447 - 454
  • [23] Interferon Alpha for Refractory Pseudophakic Cystoid Macular Edema (Irvine-Gass Syndrome)
    Dimopoulos, Spyridon
    Deuter, Christoph M. E.
    Blumenstock, Gunnar
    Zierhut, Manfred
    Dimopoulou, Anastasia
    Voykov, Bogomil
    Bartz-Schmidt, Karl-Ulrich
    Doycheva, Deshka
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2020, 28 (02) : 315 - 321
  • [24] Intraocular Methotrexate in the Treatment of Uveitis and Uveitic Cystoid Macular Edema
    Taylor, Simon R. J.
    Habot-Wilner, Zohar
    Pacheco, Patricio
    Lightman, Sue L.
    OPHTHALMOLOGY, 2009, 116 (04) : 797 - 801
  • [25] The Effectiveness of Pharmacological Agents for the Treatment of Uveitic Macular Edema (UMO): A Systematic Review
    Tallouzi, Mohammad O.
    Moore, David J.
    Barry, Robert J.
    Calvert, Melanie
    Mathers, Jonathan
    Murray, Philip, I
    Denniston, Alastair K.
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2019, 27 (04) : 658 - 680
  • [26] Safety and Effectiveness of Interferon Alpha-2a in Treatment of Patients with Behcet's Uveitis Refractory to Conventional Treatments
    Sobaci, Gungor
    Erdem, Uzeyir
    Durukan, A. Hakan
    Erdurman, Cuneyt
    Bayer, Atilla
    Koksal, Serkan
    Karagul, Suat
    Bayraktar, M. Zeki
    OPHTHALMOLOGY, 2010, 117 (07) : 1430 - 1435
  • [27] Cystoid macular edema refractory to treatment
    Rodriguez Vicente, L.
    Martin-Garcia, E.
    Chavarri-Garcia, J. J.
    Jimenez-Del Rio, B.
    Ortega-Renedo, I.
    Ibanez-Munoz, A.
    Del Rio-Mayor, J. L.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2021, 44 (04): : E211 - E213
  • [28] Topical interferon - A novel treatment for pseudophakic macular edema
    Kawali, Ankush
    Snehith, Ram
    Singh, Vivek
    Sanjay, Srinivasan
    Mahendradas, Padmamalini
    Shetty, Rohit
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2021, 69 (09) : 2355 - +
  • [29] Comparison of the Safety and Efficacy of Interferon Alpha-2a and Cyclosporine-A When Combined With Glucocorticoid in the Treatment of Refractory Behcet's Uveitis: A Randomized Controlled Prospective Study
    Qian, Yujing
    Qu, Yi
    Gao, Fei
    Pei, Minghang
    Liang, Anyi
    Xiao, Junyan
    Zhao, Chan
    Zhang, Meifen
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [30] Outcomes of Uveitic Macular Edema in the First-line Antimetabolites as Steroid-Sparing Treatment Uveitis Trial
    Tsui, Edmund
    Rathinam, Sivakumar R.
    Gonzales, John A.
    Thundikandy, Radhika
    Kanakath, Anuradha
    Balamurugan, S.
    Vedhanayaki, R.
    Lim, Lyndell L.
    Suhler, Eric B.
    Al-Dhibi, Hassan A.
    Thuy Doan
    Keenan, Jeremy
    Ebert, Caleb D.
    Kim, Eric
    Madow, Brian
    Porco, Travis C.
    Acharya, Nisha R.
    OPHTHALMOLOGY, 2022, 129 (06) : 661 - 667
12345